国际肿瘤学杂志

国际肿瘤学杂志 ›› 2013, Vol. 40 ›› Issue (4): 278-283.

• 综述 • 上一篇    下一篇

化疗所致贫血对肺癌患者的影响和治疗

何春晓,宋正波,张沂平   

  1. 310022杭州，浙江省肿瘤医院化疗中心（何春晓、宋正波、张沂平）；浙江中医药大学第二临床医学院（何春晓）
  • 出版日期:2013-04-08 发布日期:2013-03-27
  • 通讯作者: 张沂平，E-mail:zyp@medmail.com.cn E-mail:zyp@medmail.com.cn
  • 基金资助:

    浙江省医药卫生科学研究基金（2007B025）；吴阶平医学基金（320.6750.11059、320.6750.11091、320.6799.1106）

Impact and treatment of chemotherapy-induced anemia on lung cancer patients

HE  Chun-Xiao, SONG  Zheng-Bo, ZHANG  Yi-Ping   

  1. Department of Medical Oncology, Zhejiang Cancer Hospital, Hangzhou 310022, China
  • Online:2013-04-08 Published:2013-03-27
  • Contact: ZHANG Yi-ping E-mail:zyp@medmail.com.cn

PDF

1419

被引次数

2

摘要： 贫血在肺癌患者中很常见，其中一个重要原因是化疗。贫血可以引起乏力、心动过速等症状，影响患者的生活质量及治疗疗效，导致患者生存时间缩短，被认为是预测不良预后的独立因素。输注红细胞、使用促红细胞生成类药物是目前治疗肺癌患者贫血的主要措施。在血红蛋白水平明显下降之前，以促红细胞生成类药物治疗为主，尽量减少输血次数，将血红蛋白水平维持在10.0～12.0 g/dl之间，可改善患者生活质量，同时有效防止血栓形成等不良事件的发生。

关键词: 贫血, 肺肿瘤, 治疗

Abstract: Anemia is common observed in lung cancer patients, and it is mainly caused by chemotherapy. Anemia can cause several debilitating symptoms such as fatigue and tachycardia which will not only influence the patients’ quality of life and therapy effect, but also short the survival time. So anemia has been regarded as a poor independent prognostic indicator of the disease. Transfusion the erythrocyte and using the erythropoiesis stimulating agents is the main treatments of the disease. Using the erythropoiesis stimulating agents is the main treatment before the hemoglobin decreasing significantly in order to reduce the times of transfusion. Keeping the hemoglobin between 10.0-12.0 g/dl can improve the patients’ quality of life and avoid the adverse events such as thrombus formation at the same time.

Key words: Anemia, Lung neoplasms, Therapeutics